Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…
Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…
R&D Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry to the global forefront. Taiwan Supra Integration and Incubation Center (Si2C), was launched in November 2011 with the intention of…
Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…
OtoSim Inc. OtoSim’s CEO Andy Sinclair discusses the current issues surrounding otoscopy diagnosis and the potential of the company’s groundbreaking simulation technology. What was your motivation for getting involved with OtoSim Inc. originally? OtoSim’s inventors submitted an invention disclosure via the Hospital for Sick Children (SickKids) to MaRS Innovation, where I was…
Ernst & Young LLP Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED tax credit process available in Canada. What do you see as the biggest challenges of life sciences clients in…
Financial Management YFY Biotech Management Company has not always been involved in the biotech sector. How has it evolved over the years? Yuen Foong Yu Group originally began as a paper mill company, which grew alongside Taiwan as the country moved from agriculture to industry. In moving away from its traditional business…
API Industry Formosa Laboratories is one of Taiwan’s international pioneers in small molecules, entering the global arena at a very early stage. How did that decision come about? Generally speaking, Taiwan’s API industry decided to go global long before the formulation sector did. The reason is simple: the local market for APIs…
Industrial Biotech Prior to joining Life Sciences Ontario (LSO), you served as CEO of GSK Canada for a number of years. What opportunities did you see in making the switch from an MNC to an association? Having been in the pharmaceutical business for my entire career in Canada, I have always been…
EDBI/Bio One Capital As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm of the Singapore Economic Development Board (EDB) and we invest in very select industry sectors. Investments in the Biomedical Sciences…
Apposite Capital LLP As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones in the last five years? Apposite was conceived as a new venture capital (VC)/ Private equity (PE) fund that would…
Apitope Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this technology and how does it differ from other peptide-based research? Apitope was founded on a platform technology to discover peptides…
See our Cookie Privacy Policy Here
